Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Clinical trial NCT01732926 · TERMINATED
Trial details
- NCT number
- NCT01732926
- Sponsor
- Gilead Sciences
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-02
- Primary completion
- 2016-05-17
- Enrollment
- 475
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.